Preclinical CRO Global Market Opportunities And Strategies To 2033
상품코드:1596062
리서치사:The Business Research Company
발행일:2024년 11월
페이지 정보:영문 323 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
세계 전임상 CRO 시장은 2018년 37억 5,582만 달러로 평가되었으며, 2023년까지 연평균 6.0% 이상 성장할 것으로 예상됩니다.
맞춤형 의료에 대한 관심 증대
개인맞춤형 의료에 대한 관심이 높아지면서 전임상 CRO 시장의 성장을 가속했습니다. 맞춤의학은 여러 바이오마커와 유전자 변이 평가를 포함한 복잡한 시험 설계를 필요로 하는 경우가 많습니다. 전임상 CRO는 이러한 복잡한 시험을 관리하는 데 필요한 전문 지식을 보유하고 있으며, 개인 맞춤형 치료 접근법의 특정 요구에 맞는 실험 설계 및 수행에 특화된 기술을 제공합니다. 예를 들어, 2022년 10월, 과학자, 환자 및 의료 서비스 제공업체를 대표하는 미국 기반 단체인 개인화된 의학 연합(Personalized Medicine Coalition)에 따르면, 여러 유형의 암, 유전적 희귀질환, 다양한 만성 질환 및 감염성 질환을 앓고 있는 환자들을 위해 75,000개 이상의 유전자 검사 제품 및 300개 이상의 이상의 유전자 검사 제품과 300여 개의 개인맞춤형 의약품이 시판되고 있는 것으로 추정됩니다. 또한, 2022년에는 미국 식품의약국(FDA)의 신약 승인 중 34%를 개인맞춤형 의약품이 차지할 것으로 추정되며, 지난 8년 동안 개인맞춤형 의약품은 승인 건수의 25% 이상을 차지해 왔습니다. 따라서 개인맞춤형 의약품에 대한 관심이 높아지면서 전임상 CRO 시장의 성장을 견인한 것으로 분석됩니다.
목차
제1장 주요 요약
전임상 CRO - 시장의 매력과 거시경제 상황
제2장 목차
제3장 표 리스트
제4장 그래프 리스트
제5장 보고서 구성
제6장 시장 특징
일반적인 시장의 정의
개요
전임상 CRO 시장 정의와 세분화
시장 세분화 : 서비스별
생체 분석 및 DMPK 연구
독성 시험
화합물 관리
화학
안전성 약리학
기타 서비스
시장 세분화 : 유형별
환자 유래 오가노이드(PDO) 모델
환자 유래 이종 이식 모델
시장 세분화 : 동물 모델별
소형 동물 모델
대형 동물 모델
시장 세분화 : 모델 시스템별
In vivo
In vitro
시장 세분화 : 최종사용자별
바이오의약품 기업
정부기관 및 학술기관
의료기기 기업
기타 최종사용자
제7장 주요 시장 동향
제8장 전임상 CRO 시장 : 거시경제 시나리오
COVID-19의 영향 : 전임상 CRO 시장
우크라이나 전쟁의 영향 : 전임상 CRO 시장
고인플레이션의 영향 : 전임상 CRO 시장
제9장 세계 시장 규모와 성장
시장 규모
시장 성장 실적, 2018년-2023년
시장 성장 촉진요인, 2018년-2023년
시장 성장 억제요인, 2018년-2023년
시장 성장 예측, 2023년-2028년, 2033년
시장 성장 촉진요인, 2023년-2028년
시장 성장 억제요인, 2023년-2028년
제10장 세계의 전임상 CRO 시장 : 세분화
세계의 전임상 CRO 시장 : 서비스별, 분석과 예측, 2018년-2023년, 2028년, 2033년
세계의 전임상 CRO 시장 : 유형별, 분석과 예측, 2018년-2023년, 2028년, 2033년
세계의 전임상 CRO 시장 : 동물 모델별 :, 분석과 예측, 2018년-2023년, 2028년, 2033년
세계의 전임상 CRO 시장 : 모델 시스템별, 분석과 예측, 2018년-2023년, 2028년, 2033년
세계의 전임상 CRO 시장 : 최종사용자별, 분석과 예측, 2018년-2023년, 2028년, 2033년
제11장 전임상 CRO 시장 : 지역·국가별 분석
세계의 전임상 CRO 시장 : 지역별, 분석과 예측, 2018년-2023년, 2028년, 2033년
세계의 전임상 CRO 시장 : 국가별, 분석과 예측, 2018년-2023년, 2028년, 2033년
Asahi Kasei Medical Co. Ltd Acquired Bionova Scientific LLC
Altasciences Acquired Sinclair Research
Thermo Fisher Scientific Inc. Acquired PPD Inc.
Laboratory Corporation of America Holdings(LabCorp) Acquired Toxikon Corporation
제23장 기회와 전략
세계의 전임상 CRO 시장, 2028년 : 새로운 기회를 제공하는 국가
세계의 전임상 CRO 시장, 2028년 : 새로운 기회를 제공하는 부문
세계의 전임상 CRO 시장, 2028년 : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제24장 전임상 CRO 시장 : 결론과 제안
결론
제안
제품
장소
가격
프로모션
사람들
제25장 부록
LSH
영문 목차
영문목차
A preclinical contract research organization (CRO) provides outsourced research services to pharmaceutical, biotechnology and medical device companies, as well as academic institutions, primarily during the early stages of drug discovery and development.
The preclinical CRO market consists of sales, by entities (organizations, sole traders and partnerships), of preclinical CRO services that are essential for evaluating the safety, efficacy, and pharmacokinetics of drug candidates prior to their progression to clinical trials. Preclinical CROs conduct critical testing to support drug development, ensuring that potential treatments meet necessary regulatory and scientific standards before advancing to human trials.
The global preclinical CRO market was valued at $3,755.82 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 6.0%.
Increased Focus On Personalized Medicine
Increased focus on personalized medicine propelled the growth of the preclinical CRO market in the historic period. Personalized medicine frequently requires intricate study designs, including the evaluation of multiple biomarkers or genetic variants. Preclinical CROs possess the expertise needed to manage these complex studies, providing specialized skills in designing and conducting experiments tailored to the specific needs of personalized treatment approaches. For instance, in October 2022, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system) estimated that more than 75,000 genetic testing products and 300 personalized medicines were on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, personalized medicines were estimated to account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, increased focus on personalized medicine supported the growth of the preclinical CRO market during the historic period.
Innovative CRO Solutions Combine Traditional Services With Cutting-Edge Technology
Companies in the preclinical CRO market are deploying innovative CRO solutions that combine traditional services with cutting-edge technology. This integration optimizes multiple facets of clinical trials, including planning, recruitment, data management and analysis. For instance, in June 2024, Lindus Health, a UK-based clinical research organization, launched an "All-in-One Medical Device CRO" that combines traditional CRO services with unique recruitment capabilities and proprietary eClinical technology. This new offering utilizes a database of over 30 million electronic health records (EHRs) and in-house digital marketing strategies for participant recruitment. It also provides extensive in-house site capabilities, including virtual and hybrid options, as well as a network of physical community sites.
The global preclinical CRO market is fairly concentrated, with large players operating in the market. The top ten competitors in the market made up 30.6% of the total market in 2023.
Preclinical CRO Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global preclinical CRO market as it emerges from the COVID-19 shut down.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market research findings.
Benchmark performance against key competitors.
Utilize the relationships between key data sets for superior strategizing.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for preclinical CRO? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The preclinical CRO market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider preclinical CRO market; and compares it with other markets.
The report covers the following chapters
Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by service, by type, by animal model, by model system and by end user.
Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the preclinical CRO market.
Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by service, by type, by animal model, by model system and by end user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
Competitive Dashboard- Briefs on competitive dashboard of major players.
Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
Conclusions And Recommendations- This section includes recommendations for preclinical CRO providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Markets Covered:
1) By Service: Bioanalysis And DMPK Studies; Toxicology Testing; Compound Management; Chemistry; Safety Pharmacology; Others Services
2) By Type: Patient-Derived Organoid (PDO) Model; Patient Derived Xenograft Model
3) By Animal Model: Small Animal Model; Large Animal Model
4) By Model System: In Vivo; In Vitro
5) By End User: Biopharmaceutical Companies; Government And Academic Institutes; Medical Device Companies; Other End-Users
Companies Mentioned: Charles River Laboratories International, Inc.; Thermo Fisher Scientific Inc. (Pharmaceutical Product Development (PPD); Eurofins Scientific SE; Laboratory Corporation of America Holdings (Covance Inc.); ICON Plc.
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; preclinical CRO indicators comparison
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1 Executive Summary
1.1 Preclinical CRO - Market Attractiveness And Macro economic Landscape
2 Table Of Contents
3 List Of Tables
4 List Of Figures
5 Report Structure
6 Market Characteristics
6.1 General Market Definition
6.2 Summary
6.3 Preclinical CRO Market Definition And Segmentations
6.4 Market Segmentation By Service
6.4.1 Bioanalysis And DMPK Studies
6.4.2 Toxicology Testing
6.4.3 Compound Management
6.4.4 Chemistry
6.4.5 Safety Pharmacology
6.4.6 Others Services
6.5 Market Segmentation By Type
6.5.1 Patient-Derived Organoid (PDO) Model
6.5.2 Patient Derived Xenograft Model
6.6 Market Segmentation By Animal Model
6.6.1 Small Animal Model
6.6.2 Large Animal Model
6.7 Market Segmentation By Model System
6.7.1 In Vivo
6.7.2 In Vitro
6.8 Market Segmentation By End User
6.8.1 Biopharmaceutical Companies
6.8.2 Government And Academic Institutes
6.8.3 Medical Device Companies
6.8.4 Other End-users
7 Major Market Trends
7.1 Introduction Of Comprehensive Clinical Trial Services Units For End-To-End Support
7.2 Innovative CRO Solutions Combine Traditional Services With Cutting-Edge Technology
7.3 Accelerating Drug Development Pipelines With Advanced AI Platforms
